Nanoparticle to Nanoparticle Bioorthogonal Detection of Atherosclerosis
ACS Applied Materials & Interfaces · 2025
DOI: 10.1021/acsami.5c08945 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Applied Materials & Interfaces, 2025. Verfasst von María Muñoz-Hernando und 7 weiteren Autor:innen. Beteiligte Einrichtung: Grupo de Nanomedicina e Imagen Molecular, Instituto de Química Médica (IQM/CSIC), Juan de la Cierva 3, 28006 Madrid, Spain. Hauptthemen laut MEDLINE: Atherosclerosis, Nanoparticles. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Consejo Superior de Investigaciones Cient?ficas, Comunidad de Madrid, Ministerio de Ciencia, Tecnolog?a e Innovaci?n.
Abstract (Originalsprache)
In vivo identification and characterization of atherosclerosis is a promising approach for the development of novel therapies and personalized treatments. Among the methods for this in vivo identification, the use of pretargeted imaging shows very large probe uptakes and excellent selectivity. However, this approach relies on the use of antibodies which may limit their usability. In this study, we introduce a pretargeting imaging approach for atherosclerosis detection using PET that only employs nanomaterials. Here we develop the concept of nanoparticle-to-nanoparticle pretargeted imaging for atherosclerosis. Sphingomyelin solid lipid nanoparticles (sphNP) functionalized with trans-cyclooctene (TCO) were used as targeting agents and accumulated in atherosclerotic plaques. This was followed by the injection of 68Ga-doped nanotracers functionalized with tetrazine ([68Ga]Ga-IONP-Tz), which binds to the accumulated sphNP-TCO via bioorthogonal click chemistry. In vivo PET imaging showed clear uptake in the aortic arch of mice receiving the full pretargeting approach, while the control groups showed no significant signal. This nanoparticle-based pretargeting strategy enables noninvasive PET imaging of atherosclerosis without using antibodies. This approach expands the use of bioorthogonal imaging and may have potential for targeted drug delivery to atherosclerotic plaques.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Grupo de Nanomedicina e Imagen Molecular, Instituto de Química Médica (IQM/CSIC), Juan de la Cierva 3, 28006 Madrid, Spain.
- Centro Nacional de Investigaciones Cardiovasculares, CNIC, Melchor Fernández-Almagro 3, 28029 Madrid, Spain.
- Unidad de Aplicaciones Médicas de las Radiaciones Ionizantes, Centro de Investigaciones Energéticas, Medioambientales y Técnicas (CIEMAT), 28040 Madrid, Spain.
- Department of Clinical Medicine, Aarhus University, 8200 Aarhus, Denmark.
- CIBER Enfermedades Respiratorias (CIBERES), Melchor Fernández-Almagro 3, 28029 Madrid, Spain.
ORCID-Profile: Andrea Rodríguez-San Pedro, Fernando Herranz
Förderung
- Consejo Superior de Investigaciones Cient?ficas
- Comunidad de Madrid
- Ministerio de Ciencia, Tecnolog?a e Innovaci?n
- Instituto de Salud Carlos III
- H2020 European Research Council
- Pro CNIC Foundation
Zitieren
APA
Muñoz-Hernando, M., Nogales, P., Rodríguez-San Pedro, A., Ibañez, M., Morcillo, M. Á., González-Cintado, L., Bentzon, J. F., & Herranz, F. (2025). Nanoparticle to Nanoparticle Bioorthogonal Detection of Atherosclerosis. ACS Applied Materials & Interfaces. https://doi.org/10.1021/acsami.5c08945
Vancouver
Muñoz-Hernando M, Nogales P, Rodríguez-San Pedro A, Ibañez M, Morcillo MÁ, González-Cintado L, et al. Nanoparticle to Nanoparticle Bioorthogonal Detection of Atherosclerosis. ACS Applied Materials & Interfaces. 2025. doi:10.1021/acsami.5c08945
BibTeX
@article{MuozHernando2025,
author = {Muñoz-Hernando, María and Nogales, Paula and Rodríguez-San Pedro, Andrea and Ibañez, Marta and Morcillo, Miguel Ángel and González-Cintado, Leticia and Bentzon, Jacob F and Herranz, Fernando},
title = {Nanoparticle to Nanoparticle Bioorthogonal Detection of Atherosclerosis},
journal = {ACS Applied Materials & Interfaces},
year = {2025},
doi = {10.1021/acsami.5c08945}
}
EUVIMED